Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI…

Read More: https://www.businesswire.com/news/home/20240601180710/en/